Your Health, We Care
Release date: 2024-08-27 15:48:23 Recommended: 142
Alpelisib is the drug of choice for patients with PIK3CA-mutated breast cancer and offers new treatment hope for patients with advanced and metastatic breast cancer, especially those who are resistant to traditional treatments.
Drug interactions may affect the efficacy of Alpelisib treatment, and understanding these interactions can help optimize treatment.
Concomitant use with breast cancer resistance protein (BCRP) inhibitors may increase the concentration of Alpelisib, increasing the risk of toxicity. The use of BCRP inhibitors during the use of Alpelisib should be avoided as much as possible, and close monitoring for possible adverse effects is recommended if this cannot be avoided.
Alpelisib may reduce plasma concentrations of CYP2C9 substrates (e.g., warfarin), reducing the effect of these drugs. When using Alpelisib, plasma concentrations of these substrates need to be closely monitored.
Understanding drug interactions can avoid potential risks. Next, we will discuss the possible adverse effects of Alpelisib and what to do about it.
According to the data of clinical trial studies on the label, the following adverse reactions may occur during the use of the drug.
Medications can affect pancreatic function, leading to elevated lipase levels. This change can trigger abdominal pain and digestive problems, and pancreatic health needs to be taken care of.
Medications may reduce appetite and affect weight and nutrient intake. Long-term loss of appetite can lead to weight loss and malnutrition.
Understanding the adverse effects of Alpelisib can help better manage treatment. Patients should also be aware of the following medication precautions.
According to the drug instructions, the precautions for the administration of the drug include but are not limited to:
In case of severe skin reactions (e.g., SCARs), discontinue the drug immediately and consult a dermatologist. Diagnosis of SCAR requires permanent discontinuation of the drug. If the diagnosis is not confirmed, the dose may need to be adjusted to use topical corticosteroids or oral antihistamines.
Check fasting blood glucose and HbA1c before treatment to optimize control. Monitoring is done weekly initially, and every four weeks thereafter. High-risk patients require more frequent monitoring and treatment adjustments.
It is recommended that patients closely observe their own drug reactions during drug treatment, and communicate with doctors in time to better manage the symptoms of adverse reactions.
[Warm tips] Maintaining a positive mindset can help with treatment, and seeking support from family, friends or professionals when facing challenges. A good state of mind can help you cope with the changes that come with treatment.
